Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread

Cancer Immunology, Immunotherapy

Volumn 65, Issue 2, 2016, Pages 213-222

  Chawla, Sharad ^a   Warren, Timothy A ^a,b,c   Wockner, Leesa F ^c   Lambie, Duncan L J ^b,d   Brown, Ian S ^e   Martin, Thomas P C ^a   Khanna, Rajiv ^c   Leggatt, Graham R ^b   Panizza, Benedict J ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d IQ PATHOLOGY   (Australia)

^e Envoi Pathology   (Australia)

Author keywords

Galectin 1; Immunohistochemistry; Lymphocytes; Perineural spread; Perineural tumour microenvironment

Indexed keywords

GALECTIN 1; TRANSCRIPTION FACTOR FOXP3; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MOLECULE; OUTCOME ASSESSMENT; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; AGED; CANCER GRADING; CRANIAL NERVE; HEAD AND NECK TUMOR; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SKIN TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR RECURRENCE;

AGED; CRANIAL NERVES; FEMALE; GALECTIN 1; HEAD AND NECK NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84955655084     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1788-z     Document Type: Article

References (43)

1. Cakir BO, Adamson P, Cingi C (2012) Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am 20(4):419–422. doi:10.1016/j.fsc.2012.07.004
2. Panizza B, Warren TA, Solares CA, Boyle GM, Lambie D, Brown I (2013) Histopathological features of clinical perineural invasion of cutaneous squamous cell carcinoma of the head and neck and the potential implications for treatment. Head Neck 36(11):1611–1618. doi:10.1002/hed.23509
3. Solares CA, Lee K, Parmar P, O’Rourke P, Panizza B (2012) Epidemiology of clinical perineural invasion in cutaneous squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 146(5):746–751. doi:10.1177/0194599811434897
4. Lin C, Tripcony L, Keller J, Poulsen M, Martin J, Jackson J, Dickie G (2012) Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys 82(1):334–340. doi:10.1016/j.ijrobp.2010.09.040
5. ten Hove MW, Glaser JS, Schatz NJ (1997) Occult perineural tumor infiltration of the trigeminal nerve. Diagnostic considerations. J Neuroophthalmol 17(3):170–177
6. Panizza B, Solares CA, Redmond M et al (2011) Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck 34:1622–1627
7. Mbeunkui F, Johann DJ Jr (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63(4):571–582. doi:10.1007/s00280-008-0881-9
8. Schaaij-Visser TB, de Wit M, Lam SW, Jimenez CR (2013) The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 1834(11):2242–2258. doi:10.1016/j.bbapap.2013.01.029
9. Paltridge JL, Belle L, Khew-Goodall Y (2013) The secretome in cancer progression. Biochim Biophys Acta 1834(11):2233–2241. doi:10.1016/j.bbapap.2013.03.014
10. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S (2014) Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40(2):307–319. doi:10.1016/j.ctrv.2013.07.007
11. Cedeno-Laurent F, Dimitroff CJ (2012) Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J 29(8–9):619–625. doi:10.1007/s10719-012-9379-0
12. Viguier M, Advedissian T, Delacour D, Poirier F, Deshayes F (2014) Galectins in epithelial functions. Tissue Barriers 2:e29103. doi:10.4161/tisb.29103
13. Cedeno-Laurent F, Dimitroff CJ (2012) Galectin-1 research in T cell immunity: past, present and future. Clin Immunol 142(2):107–116. doi:10.1016/j.clim.2011.09.011
14. Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17. doi:10.1017/S1462399408000719
15. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013
16. Schlosser HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, Bergwelt-Baildon M (2014) Overcoming tumor-mediated immunosuppression. Immunotherapy 6(9):973–988. doi:10.2217/imt.14.58
17. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J (2010) Natural immunity to cancer in humans. Curr Opin Immunol 22(2):215–222. doi:10.1016/j.coi.2010.02.006
18. Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67(5):1883–1886. doi:10.1158/0008-5472.CAN-06-4806
19. Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC, Chen YL, Jin YT (2008) Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 44(4):325–334. doi:10.1016/j.oraloncology.2007.03.004
20. Ding YM, Dong JH, Chen LL, Zhang HD (2009) Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development. Oncol Rep 21(4):983–987
21. Alves PM, Godoy GP, Gomes DQ, Medeiros AM, de Souza LB, da Silveira EJ, Vasconcelos MG, Queiroz LM (2011) Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract 207(4):236–240. doi:10.1016/j.prp.2011.02.004
22. Tang CE, Tan T, Li C, Chen ZC, Ruan L, Wang HH, Su T, Zhang PF, Xiao ZQ (2010) Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep 24(2):495–500
23. Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A (2010) Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 16(3–4):102–115. doi:10.2119/molmed.2009.00119
24. Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, Eggert A, Schramm A (2009) Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene 28(19):2015–2023. doi:10.1038/onc.2009.70
25. Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF (2013) Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol 19(47):8831–8849. doi:10.3748/wjg.v19.i47.8831
26. Tang D, Yuan Z, Xue X, Lu Z, Zhang Y, Wang H, Chen M, An Y, Wei J, Zhu Y, Miao Y, Jiang K (2012) High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 130(10):2337–2348. doi:10.1002/ijc.26290
27. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5(3):241–251
28. Rabinovich GA, Croci DO (2012) Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 36(3):322–335. doi:10.1016/j.immuni.2012.03.004
29. Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, Jong YJ, Hung CH, Yang CJ, Tsai YM, Hsu YL, Huang MS (2011) Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol 186(3):1521–1530. doi:10.4049/jimmunol.1002940
30. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104(32):13134–13139. doi:10.1073/pnas.0706017104
31. Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, Giaccia AJ, Koong AC, Le QT (2011) Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 71(13):4423–4431. doi:10.1158/0008-5472.CAN-10-4157
32. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O’Byrne KJ, Giaccia AJ, Koong AC (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23(35):8932–8941. doi:10.1200/JCO.2005.02.0206
33. van den Brule FA, Waltregny D, Castronovo V (2001) Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193(1):80–87. doi:10.1002/1096-9896(2000)9999:9999<:AID-PATH730>3.0.CO;2-2
34. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI (2007) Galectin-1: a key effector of regulation mediated by CD4 + CD25 + T cells. Blood 109(5):2058–2065. doi:10.1182/blood-2006-04-016451
35. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG, Rabinovich GA (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8(8):825–834. doi:10.1038/ni1482
36. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8):1093–1102. doi:10.1038/onc.2009.416
37. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125(1):65–72. doi:10.1007/s10549-010-0831-1
38. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25(7):869–875. doi:10.1200/JCO.2006.08.9755
39. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8(10):3137–3145
40. Kyrgidis A, Tzellos TG, Kechagias N, Patrikidou A, Xirou P, Kitikidou K, Bourlidou E, Vahtsevanos K, Antoniades K (2010) Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer 46(9):1563–1572. doi:10.1016/j.ejca.2010.02.046
41. Csiba A, Whitwell HL, Moore M (1984) Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer 50(5):699–709
42. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huber C (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 2(8):1427–1433
43. Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F, Huber C (1996) Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56(8):1756–1760